Pioneers in pulsed field ablation

Over 15 years of robust preclinical research in IRE and clinical application of pulsed field cardiac ablation yielded the PulseSelect™ PFA system for paroxysmal and persistent AF. The Medtronic PFA suite launches a new era in safety and an exciting shift in precision and efficiency in PFA electrophysiology for atrial fibrillation treatment with the Affera™ mapping and ablation system, integrated with the only all-in-one dual-energy Sphere-9™ PFA catheter.




Versatile PFA tools to tailor lesion sets

Wide area focal

Wide area focal PFA catheters provide the ability to tailor lesion sets across the anatomy, ensuring consistent and reliable isolation.2

An all-in-one PFA solution to map, ablate, and validate, the Sphere-9™ catheter is the only wide area focal dual-energy pulsed field/radiofrequency catheter, exclusively integrated with the Affera™ mapping and ablation system.





SPHERE Per-AF — superior efficiency compared to traditional RF3

RCT IDE comparing Affera™ mapping and ablation system with Sphere-9™ catheter to CARTO®* navigation and mapping system with THERMOCOOL SMARTTOUCH®* SF (STSF) catheter

420 patients | drug-refractory persistent AF | 23 centers | 40+ operators

  • 1.4% primary safety events versus 1% when using STSF
  • 74% primary effectiveness rate
  • 80% effectiveness in more than 10 cases4
  • 25+ minutes saved per procedure

Single shot

Single-shot PFA catheters allow you to achieve wide area circumferential lesions designed with pulmonary vein isolation (PVI) in mind.

The PulseSelect™ PFA system features a single-shot over-the-wire PFA catheter, enabling mapping and precise lesion delivery with the freedom to adapt to your preferred workflow.


PULSED AF — the safest PFA IDE trial published to date.5

IDE evaluating the safety and effectiveness of the PulseSelect™ PFA system.

300 patients | drug-refractory PAF and PsAF patients | 41 centers | 67 operators


Primary safety events

0.7%


Efficacy

Freedom from AF/AT/AFL



Medtronic PFA history

Began electroporation research for cardiac surgery in 2006

  • First Medtronic PFA patent filed in 2008
  • First Medtronic publication on electroporation for cardiac ablation in 2009

Affera™ Inc. established

Medtronic partners with world-leading experts in electroporation

  • Hemolysis, esophagus, and phrenic nerve impact preclinical research

  • PULSED AF: first PFA IDE trial completed enrollment with PulseSelect™
  • First in human pulsed field cases with Sphere-9™ catheter and Sphere-360™ catheter
  • Medtronic acquires Affera™ mapping and ablation system

  • PULSED AF: safest PFA IDE trial published to date
  • Sphere-9™: first and only all-in-one dual-energy catheter launches in Europe
  • PulseSelect™: first PFA catheter for PAF and PsAF launched globally

  • Sphere-360™: 12-month follow up data published and presented at European Heart Rhythm Association
  • SPHERE Per-AF IDE trial: first and only PFA randomized clinical trial in PsAF patients published and presented at Heart Rhythm Society

Related products